Our Pricing

Wegovy Online UK: All Doses In Stock & Ready to Ship

Published on: June 03, 2026

Searching for wegovy online uk in stock with immediate availability? At Cured Pharmacy, we stock all Wegovy doses from 0.25mg to 2.4mg, with transparent pricing from £79.00, free clinical consultation under 3 minutes, and discreet next-day delivery across the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the action of glucagon-like peptide-1, a naturally occurring hormone that regulates appetite and food intake by acting on receptors in the brain.

In the landmark STEP 1 trial, participants using Wegovy alongside lifestyle interventions achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing hunger signals, and increasing feelings of fullness after meals, making it easier to adhere to a reduced-calorie diet.

Wegovy is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The treatment follows a gradual dose escalation protocol starting at 0.25mg, increasing every four weeks to minimise gastrointestinal side effects, with a maintenance dose of 2.4mg [2].

Wegovy Dosing Schedule and Availability

The complete Wegovy dosing schedule includes five escalation doses followed by the maintenance dose. Your UK prescriber will determine your starting point based on your clinical history and treatment goals, though most patients begin at the lowest dose.

At Cured Pharmacy, we maintain stock of all Wegovy doses: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and the 2.4mg maintenance dose. Unlike periods of national shortage experienced in 2023, current supply chains are stable, allowing us to dispense prescriptions without delay.

Each Wegovy pen is a pre-filled, single-dose injector designed for ease of use. The pen should be stored in a refrigerator between 2°C and 8°C before first use, and can be kept at room temperature (up to 30°C) for up to 28 days once in use [2].

Dose Escalation Timeline

The gradual escalation protocol is clinically important for tolerability. Rushing through doses or skipping steps significantly increases the risk of nausea, vomiting, and diarrhoea. Your prescriber may recommend staying at a lower dose for longer if you experience persistent side effects, or may advise discontinuation if symptoms don't resolve within the escalation period.

Clinical Evidence: STEP Trial Programme

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme evaluated semaglutide 2.4mg across multiple patient populations. STEP 1 enrolled 1,961 adults with obesity or overweight with weight-related comorbidities, demonstrating that 86.4% of participants on Wegovy achieved at least 5% weight loss, compared to 31.5% on placebo [1].

STEP 2 specifically examined patients with type 2 diabetes, showing an average weight reduction of 9.6% with Wegovy versus 3.4% with placebo over 68 weeks [3]. This trial confirmed that semaglutide's weight loss efficacy extends to metabolically complex populations, though the magnitude of effect was somewhat lower than in non-diabetic participants.

Long-term data from STEP 5 followed participants for 104 weeks, with those on continuous Wegovy treatment maintaining an average 15.2% weight loss from baseline [4]. Notably, the STEP 4 withdrawal trial demonstrated that discontinuing Wegovy led to significant weight regain, underscoring that this is a chronic treatment requiring ongoing use to sustain benefits.

Real-World Effectiveness

While clinical trials provide controlled evidence, real-world effectiveness can vary based on adherence, lifestyle modifications, and individual metabolic factors. UK prescribers typically recommend combining Wegovy with a reduced-calorie diet (approximately 500-1000 kcal deficit) and at least 150 minutes of moderate-intensity physical activity per week, consistent with NICE guidance on obesity management.

Common Side Effects and Management

The most frequently reported side effects with Wegovy are gastrointestinal: nausea (44% of participants in STEP 1), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are typically mild to moderate, most common during dose escalation, and tend to diminish over time as the body adapts to the medication.

To minimise gastrointestinal symptoms, our clinical team recommends eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection at the same time each week. If you miss a dose by more than five days, you should skip that dose and resume your regular schedule with the next injection.

Serious but rare adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking other glucose-lowering medications). Wegovy carries a boxed warning in the US regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2].

How to Order Wegovy Online UK from Cured Pharmacy

Ordering Wegovy through Cured Pharmacy begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications. This assessment is reviewed by a UK-registered prescriber, typically within hours during working days.

If your prescriber approves Wegovy as clinically appropriate, your prescription is sent electronically to our dispensing pharmacy. We use 100% discreet packaging with no external branding, and offer next-day delivery across the UK mainland. All medications are genuine UK-licensed products stored and handled according to GPhC standards.

Pricing is transparent before you complete your consultation. Wegovy starts from £79.00 at Cured Pharmacy, representing competitive UK pricing with no hidden fees or subscription requirements. Your prescriber will specify the appropriate dose based on where you are in the escalation schedule, and you can reorder subsequent doses through your patient account as you progress through the treatment protocol.

Ongoing Clinical Support

Weight management with Wegovy is a long-term commitment, and our clinical team remains available throughout your treatment journey. If you experience side effects, have questions about dose progression, or need guidance on combining Wegovy with lifestyle changes, you can contact our pharmacy team on (+44) 116 4646009 or through your online account. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services to ensure safe, evidence-based care.

Wegovy vs Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms, efficacy profiles, and administration routes. Semaglutide-based Wegovy represents the current benchmark for injectable GLP-1 treatments, though newer dual-agonist medications are showing even greater weight loss in clinical trials.

Saxenda contains liraglutide, an earlier-generation GLP-1 agonist requiring daily injections rather than weekly. While effective, with an average weight loss of 8% in the SCALE trial programme, the daily injection burden and lower magnitude of effect make it less convenient for many patients compared to Wegovy's once-weekly dosing [5].

Oral medications like Orlistat (also marketed as Xenical) and Mysimba work through entirely different pathways. Orlistat blocks fat absorption in the gut, producing modest weight loss of approximately 3-5% but with notable gastrointestinal side effects. Mysimba combines naltrexone and bupropion to reduce appetite and cravings, with efficacy between oral and injectable GLP-1 options. Your UK prescriber will discuss which treatment aligns best with your medical history, weight loss goals, and lifestyle preferences.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity.